Stent Thrombosis After Short-term Discontinuation of Ticagrelor for Coronary Artery Bypass Grafting

Seung Hyuk Nam; Hyuck Kim; Sun Kyun Ro

doi:10.1016/j.athoracsur.2019.05.057

Stent Thrombosis After Short-term Discontinuation of Ticagrelor for Coronary Artery Bypass Grafting

Ann Thorac Surg. 2020 Apr;109(4):e289-e291. doi: 10.1016/j.athoracsur.2019.05.057. Epub 2019 Jul 11.

Authors

Seung Hyuk Nam¹, Hyuck Kim², Sun Kyun Ro³

Affiliations

¹ Department of Thoracic and Cardiovascular Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.
² Department of Thoracic and Cardiovascular Surgery, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.
³ Department of Thoracic and Cardiovascular Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea. Electronic address: skro@hanyang.ac.kr.

PMID: 31302083
DOI: 10.1016/j.athoracsur.2019.05.057

Abstract

The optimum antithrombotic strategy before open heart surgery in patients with recently implanted coronary stents has not been clearly established because of lack of clinical evidence. This report describes a case of stent thrombosis in a patient who discontinued a P2Y₁₂ inhibitor (ticagrelor) for 3 days before coronary artery bypass grafting. The period of withdrawal of antiplatelet drugs before coronary artery bypass grafting should be minimized in patients with recently implanted drug-eluting coronary stents to prevent stent thrombosis.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Coronary Artery Bypass*
Humans
Male
Platelet Aggregation Inhibitors / administration & dosage*
Postoperative Complications / etiology*
Stents / adverse effects*
Thrombosis / etiology*
Ticagrelor / administration & dosage*
Time Factors
Withholding Treatment

Substances

Platelet Aggregation Inhibitors
Ticagrelor